The role of both genetic and pharmacological agents in the inhibition of astrocytic Mysm1 to alleviate depressive‐like disorders suggests that astrocytic Mysm1 may be a valuable target for drug discovery in depression. This evidence concerns the gene MYSM1 and depressive symptom measurement.